Gary Lyman, MD, MPH, co-director of the Hutchinson Institute for Cancer Outcomes Research (HICOR) discusses the inspiration, key findings, and overall goals of HICOR’s first-of-its-kind community cancer care report, “Community Cancer Care in Washington State: Quality and Cost Report.”
A recent review proposes a new form of research that includes cancer researchers as the primary drivers of the process and outlines the benefits of the model in relation to potential improved cost benefits.
Nathan R Handley, MD, explains the extent to which unplanned acute hospital care is a concern for the health care system and ways in which care coordination and clinical pathways can help decrease unnecessary spending.
A systematic review of value-based health care delivery models in oncology care found that reports of outcomes are often lacking and show varying degrees of quality improvement.
Richard Kane, MIPP, MA, and Josh Seidman, PhD, MHS, both with Avalere Health, share their thoughts on the intricacies of the MACRA Merit-Based Incentive Payment System and the risk practices must accept when transitioning to the Oncology Care Model.
Ray D Page, DO, PhD, addresses how including drug costs in bundled payments places oncology practices at the uncontrollable probabilistic risk of patient case mixes.
Sowmya Josyula, MD, MPH, and Bobby Daly, MD, MBA, discuss the most commonly recognized administrative barriers faced by physicians using oncology clinical pathways and argue that addressing these burdens is crucial in ensuring provider adoption and seamless patient care.
Bijal Shah-Manek, BPharm, PhD, discusses oncologist perceptions of drug affordability and ways to improve existing value frameworks.
Allen Lichter, MD, FASCO, delves into the growing concern of financial toxicity among stakeholders in the cancer community and the efforts of the Value in Cancer Care Consortium to improve the access, affordability, and value of cancer therapies.
Dawn Holcombe, MBA, FACMPE, ACHE, explains why private payers are making the transition from traditional reimbursement models to value-based models at a slow pace and how OCM performance results may impact this transition.